Aktiesnakken — Oktober 2009
-
-
?The approval of Arzerra marks a key milestone for Genmab as it is our first antibody to reach the market. We are happy that we can now offer a new treatment to these refractory CLL patients, especially as it is Genmab?s goal to develop products for life
-
hold da op
-
fantastisk....
-
takker NPO...
-
har tjekket inboxen... det er nice.
-
wauw!! helt vildt godt! Tillykke til genmab og alle aktionærene.
-
hallooooO!!!
-
-
men total overraskelse det kommer i dag....
-
sover du ik aka
-
jeg havde en god fornemmelse om det ville komme før
-
tiløk
-
coller sendte sms!!!
-
sjældent har det været så godt at se en mail i inboxen fra niecen........
-
Lucy McNiece
-
halleleluja
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind